Influenza Virus Infections and Infestations
Conditions
Interventions
A total of up to 240 participants will be randomised to receive one of four active treatments via a single intramuscular injection.
Part A (n = up to 120, randomised 1:1 for n = 50 evaluable particip
the exact treatments will be determined based on emerging data.
A designated unblinded statistician, separate from the conduct or analysis of the study, will be responsible for the computer-generated
Sponsors
hVIVO Services Ltd.
Eligibility
Sex/Gender
All
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: 1. An informed consent document signed and dated by the subject and the investigator. 2. Males and females 18 to 55 years inclusive on the day of signing the consent form. 3. A total body weight =50 kg and body mass index (BMI) =18 kg/m2 and =35kg/m2. 4. In good health with no history, or current evidence, of clinically significant medical conditions, and no clinically significant test abnormalities that will interfere with participant safety, as defined by medical history, physical examination, (including vital signs), ECG, and routine laboratory tests as determined by the investigator. 5. Participants will have a documented medical history either prior to entering the study or following medical history review with the study physician at screening. 6. The following criteria are applicable to female participants participating in the study. 6.1. Females of childbearing potential must have a negative pregnancy test prior to enrolment. 6.2. Females of non-childbearing potential: 6.2.1. Postmenopausal females defined as amenorrhea for =12 months with no alternative medical cause. A high follicle-stimulating hormone (FSH) level, within appropriate postmenopausal range, may be used to confirm postmenopausal state in the absence of combined hormonal contraception or hormone replacement therapy. If there is <12 months of amenorrhea, 2 FSH samples are required at least 4 to 6 weeks apart. 6.2.2. Documented status as being surgically sterile (e.g., tubal ligation, hysterectomy, bilateral salpingectomy, and bilateral oophorectomy). 7. The following criteria apply to female and male participants: 7.1. Female participants of childbearing potential must use 1 or more highly effective contraception. Hormonal methods must be in place from at least 2 weeks prior to the first study visit. The contraception use must continue until 28 days after the date of viral change. Highly effective contraception is as described below: Established use of hormonal methods of contraception described below (for a minimum of 2 weeks prior to first study visit). When hormonal methods of contraception are used, male partners are required to use a condom with a spermicide. 7.2. Combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation: 7.2.1. oral 7.2.2. intravaginal 7.2.3. transdermal 7.3. progestogen-only hormonal contraception associated with inhibition of ovulation: 7.3.1. oral 7.3.2. injectable 7.3.3. implantable 7.4 Intrauterine device 7.5. Intrauterine hormone-releasing system 7.6. Bilateral tubal ligation 7.7. Male sterilisation (with the appropriate post vasectomy documentation of the absence of sperm in the ejaculate) where the vasectomised male is the sole partner for that woman. 7.8. True abstinence -sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the participant. 8. Serosuitable for the challenge virus
Exclusion criteria
Exclusion criteria: 1. History of, or currently active, symptoms or signs suggestive of upper or lower respiratory tract (LRT) infection within 4 weeks prior to the first study visit. 2. Any history or evidence of any clinically significant or currently active cardiovascular, respiratory, dermatological, gastrointestinal, endocrinological, haematological, hepatic, immunological (including immunosuppression), metabolic, urological, renal, neurological, or psychiatric disease and/or other major disease that, in the opinion of the PI/investigator may interfere with a participant completing the study and necessary investigations. Any other major disease that, in the opinion of the Investigator, may put the subject at undue risk, or interfere with a subject completing the study and necessary investigations. Other conditions may apply as per protocol. 3. Any participants who have smoked =10 pack years at any time (10 pack years is equivalent to one pack of 20 cigarettes a day for 10 years). 4. Female participants who: 4.1. Are breastfeeding, or 4.2. Have been pregnant within 6 months prior to the study, or 4.3. Have a positive pregnancy test at any point during screening or prior to inoculation. 5. Lifetime history of anaphylaxis and/or a lifetime history of severe allergic reaction. Significant intolerance to any food or drug in the last 12 months, as assessed by the PI. 6. Venous access deemed inadequate for the phlebotomy and cannulation demands of the study. 7.1. Any significant abnormality altering the anatomy of the nose in a substantial way or nasopharynx that may interfere with the aims of the study and, in particular, any of the nasal assessments or viral challenge (historical nasal polyps can be included, but large nasal polyps causing current and significant symptoms and/or requiring regular treatments in the last month will be excluded). 7.2. Any clinically significant history of epistaxis (large nosebleeds) within the last 3 months of the first study visit and/or history of being hospitalised due to epistaxis on any previous occasion. 7.3. Any nasal or sinus surgery within 3months of the first study visit. 8.1. Evidence of vaccinations within the 4weeks prior to the planned date with vaccine. 8.2. Intention to receive any vaccination(s) before the last day of follow-up. 8.3. No travel restrictions apply after the Day 28 [±3 days] follow-up visit. 9. Receipt of blood or blood products, or loss (including blood donations) of 550mL or more of blood during the 3 months prior to the planned dosing with vaccine or planned during the 3months after the final visit. 10.1. Receipt of any investigational drug within 3 months prior to the planned date of dosing with vaccine. 10.2. Receipt of 3 or more investigational drugs within the previous 12months prior to the planned date of dosing with vaccine. 10.3. Prior inoculation with a virus from the same virus-family as the challenge virus. 10.4. Prior participation in another HVC study with a respiratory virus in the preceding 3 months, taken from the date of viral challenge in the previous study to the date of expected viral challenge in this study. 11.1. Use or anticipated use during the conduct of the study of concomitant medications (prescription and/or non-prescription), including vitamins or herbal and dietary supplements within the specified windows, unless in the opinion of the study physician/PI, the medication will not interfere with the study procedures or compromise participant safety. 11.2. Ov
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the reduction in one or more of the following endpoints within the primary endpoint family: 1. Area under the viral load-time curve (VL-AUC) of influenza challenge virus as determined by qRT-PCR on nasal samples collected twice daily starting from Day 1 (pm) up to planned discharge from quarantine (Day 8, am) 2. Peak viral load of influenza as defined by the maximum viral load determined by quantifiable qRT-PCR measurements on nasal samples collected twice daily starting from Day 1 (pm) up to planned discharge from quarantine (Day 8, am) 3. RT-PCR-confirmed moderately severe influenza infection, defined as: 3.1. RT-PCR-confirmed influenza infection (two quantifiable [=lower limit of quantification {LLOQ}] qRT-PCR measurements [reported on 2 or more consecutive days], starting from Day 1 [pm] up to planned discharge from quarantine [Day 8, am]), AND 3.2. Any symptoms of grade =2 at a single timepoint 4. RT-PCR-confirmed febrile influenza infection, defined as: 4.1. RT-PCR-confirmed influenza infection (two quantifiable [=LLOQ] qRT-PCR measurements [reported on two or more consecutive days], starting from Day 1 [pm] up to planned discharge from quarantine [Day 8, am]), AND 4.2. A temperature of =37.9ºC from Day 1 up to planned discharge from quarantine (Day 8, am) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. VL-AUC of influenza challenge virus as determined by tissue culture on nasal samples collected twice daily starting from Day 1 (pm) up to planned discharge from quarantine (Day 8, am) 2. VLPEAK of influenza as defined by the maximum viral load determined by quantitative viral culture measurements in nasal samples collected twice daily starting from Day 1 (pm) up to planned discharge from quarantine (Day 8, am) 3. Duration of quantifiable influenza, assessed by qRT-PCR measurements in nasal samples, starting from Day 1 (pm) up to planned discharge from quarantine (Day 8, am). Duration is defined as the time (hours) from first quantifiable (=LLOQ) until first confirmed <LLOQ assessment after their peak measure (after which no further virus is quantified) 4. Duration of quantifiable influenza viral culture measurements in nasal samples, starting from Day 1 (pm) up to planned discharge from quarantine (Day 8, am). Duration is defined as the time (hours) from first quantifiable (=LLOQ) until first confirmed <LLOQ assessment after their peak measure (after which no further virus is quantified) 5. RT-PCR-confirmed influenza infection defined as two quantifiable (=LLOQ) RT-PCR measurements (reported on two or more independent nasal samples over 2 days), starting from Day 1 (pm) up to planned discharge from quarantine (Day 8, am) 6. RT-PCR-confirmed symptomatic influenza infection, defined as: 6.1. RT-PCR-confirmed influenza infection (two quantifiable [=LLOQ] qRT-PCR measurements [reported on two or more consecutive days], starting from Day 1 [pm] up to planned discharge from quarantine [Day 8, am]), AND 6.2. Symptom score totalling =2 at a single timepoint 7. Area under the curve over time of total symptoms score (TSS-AUC) as measured by graded symptom scoring system collected three times daily, starting from Day 1 (am) up to planned discharge from quarantine (Day 8, am). 8. Peak daily symptom score: individual maximu | — |
Countries
United Kingdom
Outcome results
None listed